Bipolar Disorder | Disease Landscape and Forecast | G7 | 2018
Bipolar disorder (BPD) is a spectrum disorder that encompasses two symptom domains: mania and depression. BPD treatment is usually initiated with atypical antipsychotics and antiepileptic drugs (AEDs); their long-standing stronghold as patient-share leaders contributes to the challenges that branded therapies face entering this crowded generic market. However, treatments with the potential to sufficiently address mania and depression will drive growth of the market. Newer-to-market therapies (e.g., Allergan/Gedeon Richter’s Vraylar/Reagila, Lundbeck/Otsuka Pharmaceutical’s Rexulti/RXulti) continue to be incorporated in the treatment paradigm, and emerging therapies (e.g., NeuroRx’s NRX-100/NRX-101) are hoping to demonstrate their ability to fulfill additional unmet needs in BPDtreatment.
Questions Answered:
- What factors drive and constrain the use of branded atypical antipsychotics in the treatment of BPD? What branded therapy is expected to experience the greatest commercial success during the forecast period?
- Given the crowded and highly genericized BPDtherapymarket, what is the commercial potential of key late-phase emerging therapies for BPD?
- What are the greatest areas of unmet need in the treatment of BPD, and how are emerging therapies expected to address these unmet needs?
- Effective treatment of BPD-associated cognitive impairment is a great unmet need in this market. To what extent will emerging therapies capitalize on this unmet need? How will physicians likely incorporate these treatments into their clinical practice?
Product description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Eighteen country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.
Epidemiology: Lifetime prevalence of BPD by country; diagnosed- and drug-treated prevalence of BPD by country.
Emerging therapies: Phase II: 13 drugs; Phase III: 11 drugs; preregistration: 3 drugs; launched: 1 drugs. Coverage of 8 preclinical and Phase I products.
Market forecast features: Ten-year, annualized, patient-based market forecast extending through 2027, segmented by brands/generics.
Key companies: Allergan, Alkermes, AstraZeneca, Eli Lilly, Gedeon Richter, GlaxoSmithKline, Indivior, Janssen, Lundbeck, Minerva Neurosciences, NeuroRx, Noven Pharmaceuticals, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon/Sunovion Pharmaceuticals, Takeda Pharmaceutical.
Key drugs: ALKS-3831, ALKS-5461, aripiprazole, esketamine, lamotrigine IR/XR, Latuda (lurasidone), lithium, lumateperone (ITI-007), NRX-100/NRX-101, , Perseris (risperidone one-month depot, RBP-7000), rapastinel, Rexult/RXulti (brexpiprazole), Risperdal Consta (risperidone microspheres depot), roluperidone (MIN-101), Seroquel IR/XR (quetiapine IR/XR), Trintellix/Brintellix (vortioxetine), Vraylar/Reagila (cariprazine), Wellbutrin IR/SR/XL.
